8,500 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Sava Infond d.o.o.

Sava Infond d.o.o. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,500 shares of the company’s stock, valued at approximately $206,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at approximately $672,000. Means Investment CO. Inc. lifted its position in shares of Hims & Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company’s stock worth $1,210,000 after acquiring an additional 9,508 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after acquiring an additional 146,621 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at $2,628,000. Finally, Pacer Advisors Inc. bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $374,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $31.96 on Friday. The firm has a market cap of $7.10 billion, a P/E ratio of 72.63 and a beta of 1.37. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The stock has a 50 day simple moving average of $39.85 and a two-hundred day simple moving average of $29.27.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on HIMS. Truist Financial lifted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Bank of America increased their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday, March 18th. Finally, Piper Sandler boosted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $37.31.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 67,687 shares of the company’s stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $34.84, for a total value of $2,358,215.08. Following the sale, the chief operating officer now owns 751,243 shares in the company, valued at approximately $26,173,306.12. This represents a 8.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,061,718 shares of company stock valued at $37,894,395 in the last three months. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.